GNTA (GNTA) Stock Price & Analysis
GNTA (GNTA) fell 11.11% to USD 1.6 as of June 10, 2026 at 05:12 UTC, according to Nexqual real-time market data.
GNTA last closed at USD 1.8; the session ranged USD 1.57–1.85 on volume of 449,233 shares. Market capitalization is $37.75M, with a 52-week range of USD 0.55–10 (NCM). Source: Nexqual, June 10, 2026 at 05:12 UTC.
Key Statistics (as of June 10, 2026 at 05:12 UTC)
| Price | USD 1.6 |
|---|---|
| Change | ▼ 11.11% (down) |
| Previous Close | USD 1.8 |
| Open | USD 1.76 |
| Day Range | USD 1.57 – 1.85 |
| 52-Week Range | USD 0.55 – 10 |
| Volume | 449,233 shares |
| Market Cap | $37.75M |
| Exchange | NCM |
Technical Analysis (GNTA)
Nexqual's technical model rates GNTA "BUY" based on 5 bullish and 1 bearish signals across 123 daily candles, as of June 10, 2026 at 05:12 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 70.12 (overbought) |
| vs SMA50 | Above (USD 0.84) |
| MACD | 0.34 (positive) |
Analyst Ratings (GNTA)
Wall Street analysts rate GNTA "None", per Nexqual as of June 10, 2026 at 05:12 UTC.
| Consensus Rating | None |
|---|
Earnings (GNTA)
Source: Nexqual, June 10, 2026 at 05:12 UTC.
Financials & Fundamentals (GNTA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -38.03% |
| Debt / Equity | 34.81 |
| Current Ratio | 14.16 |
| Total Cash | $28.15M |
| Total Debt | $7.60M |
| Free Cash Flow | $-3.10M |
Source: Nexqual, June 10, 2026 at 05:12 UTC.
Financial Health Score (GNTA)
Nexqual rates GNTA's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 05:12 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $28M cash vs $8M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$7M |
| Efficiency | Critical — ROE -38%, ROA -17.7% |
Ownership (GNTA)
| Insider Ownership | +44.60% |
|---|---|
| Institutional Ownership | +7.40% |
| Shares Outstanding | 23.59M |
| Float | 13.87M |
| Short % of Float | +1.49% |
Source: Nexqual, June 10, 2026 at 05:12 UTC.
Leadership (GNTA)
GNTA is led by Pierluigi Paracchi (age 52), Co-Founder, Chairman, CEO & GM, per Nexqual as of June 10, 2026 at 05:12 UTC.
| Co-Founder, Chairman, CEO & GM | Pierluigi Paracchi (age 52) |
|---|---|
| Co-Founder & Chairman of Scientific Advisory Board | Luigi Naldini (age 66) |
| Vice President Corporate Development | Gianfranco De Nigris |
| Chief Medical Officer, Head of Development & Director | Francesco Galimi (age 57) |
| Director of Program Development | Stefania Mazzoleni (age 43) |
Major Backers & Investors (GNTA)
Notable institutional backers of GNTA include Eurizon Capital Sgr S.p.a., Alti Global, Inc., Smartharvest Portfolios, LLC, according to Nexqual as of June 10, 2026 at 05:12 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Eurizon Capital Sgr S.p.a. | 1.53% |
| Alti Global, Inc. | 0.85% |
| Smartharvest Portfolios, LLC | 0.57% |
| Independent Advisor Alliance | 0.16% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Allianz SE | 0.99% |
Source: Nexqual, June 10, 2026 at 05:12 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CASIF | CASI Pharmaceuticals, Inc. | USD 0.1 | ▼ 21.54% |
| XOMA | XOMA Royalty Corporation | USD 41.95 | ▼ 0.33% |
| TGEN | Tecogen Inc. | USD 5.67 | ▼ 1.22% |
| NGEN | NervGen Pharma Corp. | USD 1.81 | ▼ 2.69% |
| OSCI | Osceola Gold, Inc. | USD 0.1 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:12 UTC. This page is informational and not investment advice.